In 2019, Hartley LLP filed a lawsuit on behalf of BSL Pharma that alleged Inovio Pharmaceuticals refused to honor its obligation to supply needle-free syringes, called Zetajets, to BLS. Zetajets were needed for BLS’s testosterone therapy drug-device combination (DDC). BLS’s DDC, which presented a clear path to FDA approval, was the only one of its kind and would have permitted patients to administer testosterone in their own homes without the expense, discomfort and infection risk of a needle puncturing the skin. Despite receiving a purchase order, issuing an invoice and receiving payment, Inovio flatly refused to supply the syringes and provided no legitimate reason for the breach. Mere weeks before trial, the case settled for a substantial amount, multiples more than the client expected.
“Through Covid-19 interruptions, an extended discovery process, battling expert witnesses, and obstacles a small company can’t imagine when they begin the journey, Hartley was there in the thick of it. They kept the expenses to a bearable amount and were transparent to us in their handling of the case at every point, giving us the good and bad for every action, response, and decision point,” said BLS President, Mark Logomasini. “It was a team victory with Hartley’s game plan and in-game management the reason we were able to achieve a favorable outcome. This is an exceptional group of people that you want on your side (You certainly don’t want to face them.)”
